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Introduction
The ‘normal’ menstrual cycle is initiated and progresses 
over 28–31 days. Plasma steroid hormone and peptide level 
fluctuation across phases is necessary to support the regula-
tory feedback mechanisms needed for normal reproductive 
functioning. For example, oestradiol and progesterone 
levels are at their lowest during menses (days 1–8), oestra-
diol increases over the follicular phase to peak just before 
ovulation. Following ovulation, oestradiol and progesterone 
levels both increase, peaking during the mid-luteal phase 
then declining towards onset of menses at Day 1.1
Sex steroids influence neuronal plasticity, though most 
estimates of direct effect are derived from animal studies.2–4 
Depending on concentration, oestradiol and progesterone 
can either protect or damage neurones.5–7 Steroid metabo-
lism can lead to redox cycling and the formation of free 
radicals, leading to cell death or ischaemia.8 The formation 
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of the progesterone metabolite allopregnanolone modulates 
gamma-aminobutyric acid (GABA) and can produce a seda-
tive effect which may slow information processing and 
adversely affect cognition9,10 and may also lower mood.11
Menstrual phase–related changes in sex steroid levels can 
influence region-specific glucose metabolism12 and brain 
activation.13 It is therefore possible that these differences 
may result in altered cognitive performance similarly to 
effects seen in pregnancy.14,15 However, assessment of cog-
nitive performance across the menstrual cycle has produced 
conflicting results.16–26 This may be due to methodological 
differences, but inaccuracy of self-reported menstrual cycle 
phase day may also influence results.
As well as affecting cognitive performance, any alteration 
in activation of the amygdala, a brain region involved in 
emotional processing, may lead to alterations in wellbeing. 
Premenstrual syndrome (PMS) is relatively common affect-
ing between 40% and 90% of women. PMS occurs typically 
in the late luteal period when oestradiol and progesterone 
levels are declining prior to the onset of menses.27–30 
Symptoms include mild adverse somatic and cognitive 
effects, mood lability, anxiety and feelings of loss of con-
trol.26,29,31 In studies investigating the association between 
hormone fluctuation and cognition, it is therefore important 
to assess emotional wellbeing as variation may adversely 
affect cognitive performance.31–33
It remains unclear what the effects of fluctuations in hor-
mone and peptide levels across the menstrual cycle have on 
cognitive function and wellbeing, if any. The accuracy of 
self-reported stage of the menstrual cycle is also unclear. 
This investigation aims to assess study feasibility and the 
accuracy of self-reported menstrual cycle phase.
Materials and methods
A total of 12 women were recruited from the staff of a hospi-
tal in the north of England. Women over the age of 18, who 
reported they had a ‘normal’ menstrual cycle were included, 
that is, they had a regular monthly 28–31 day cycle. The 
women included were not planning a pregnancy and were 
not using any form of hormonal contraception. Those taking 
any prescription or regular non-prescription medication were 
excluded as were those with psychiatric or medical condi-
tions. Study information was provided and written consent 
obtained.
Assessments were undertaken in the woman’s self-
reported follicular and luteal phases. Self-reported stage 
was assessed by each woman based on the date of the start 
of their current menstrual period, that is, counting forwards; 
this was then confirmed by counting backwards from the 
start of their subsequent menstrual period. If there was a 
discrepancy (2 or more days) between phase estimation 
using these two methods, data were not included. Half the 
participants were assessed first during their self-reported 
follicular phase, ideally during menstruation, then 3 months 
later during the mid-luteal phase (group 1). The remaining 
participants undertook assessments first during their self-
reported luteal phase and then 3 months later during the fol-
licular phase (group 2). Figure 1 shows participant flow 
through the study. This cross-over design was used with the 
aim of precluding order and learning effects that may occur 
when repeated assessments are undertaken in this way. 
Phase of cycle was estimated first by self-report, then by 
plasma hormone and peptide assay. Venous blood samples 
were drawn at the time of each cognitive and wellbeing 
assessment. Approvals were obtained from the Bradford 
Research Ethics Committee (05/Q1202/123) and Bradford 
Teaching Hospitals National Health Service (NHS) 
Foundation Trust research department and the study was 
carried out according to research governance guidance.34
Data collection tools
The Cambridge Neuropsychological Test Automated Battery.  
The Cambridge Neuropsychological Test Automated Battery 
(CANTAB) is a computer-based psychometric test battery,35 
providing a fast, precise, language-independent accurate and 
objective assessment of ability, relative to more traditional 
pen and paper tools.36,37 CANTAB® is designed in a game-
like format, providing feedback which helps maintain moti-
vation.36 Four tests were chosen from the battery that assess 
aspects of executive function: (a) the ability to plan or strate-
gize and (b) shift attention (stockings of Cambridge (SOC) 
and intra/extra dimensional (IED) shift tests) and two that 
assess aspects of working memory, which is a component of 
executive function38 (c) immediate and delayed perceptual 
matching (delayed matching to sample (DMS) test) and (d) 
spatial memory (spatial recognition memory (SRM) test).
SRM test. The SRM test is a two-choice forced discrimina-
tion task, assessing spatial memory, completed in approxi-
mately 5 min depending on level of ability. The participant is 
presented with a white square, which appears in sequence at 
five different locations on the screen. In the recognition 
phase, the participant sees a series of five pairs of squares, 
Figure 1. Participant flow through the study.
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one of which is in a place previously seen in the presentation 
phase. The other square is in a location not previously seen. 
Locations are tested in the reverse of the presentation order. 
This task is repeated three more times, each time with five 
new locations.
DMS test. The DMS test assesses forced choice recognition 
memory for novel non-verbalisable patterns. DMS is a test 
of simultaneous and DMS, assessing short-term working 
memory and is completed in approximately 10 min. The 
participant is shown a complex visual pattern (the sample) 
and then, following a brief delay, four similar patterns are 
presented. Task difficulty is manipulated by varying the 
delay before the 4 response stimuli are presented 
(0–1200 ms).
SOC test. The SOC test assesses spatial planning ability and 
is completed in approximately 10 min depending on level of 
ability. The participant is shown two displays containing 
three coloured balls. The displays are presented in a way 
where they can be perceived as stacks of coloured balls held 
in stockings suspended from a beam. The participant must 
use the balls in the lower display to copy the pattern shown 
in the upper display. The balls may be moved one at a time 
by touching the required ball, then touching the position to 
which it should be moved.
IED shift test. The IED shift test assesses rule acquisition 
and attentional set shifting ability to discriminate between 
patterns, to reverse a correct and reinforced response and to 
shift attention from one perceptual aspect of a pattern to 
another. The test is completed in approximately 7 min and 
consists of a series of two alternative forced choice patterns 
presented in nine fixed order stages. Two artificial dimen-
sions are used in the test, colour-filled shapes and white 
lines.
Edinburgh Postnatal Depression Scale. The Edinburgh Postna-
tal Depression Scale (EPDS) is a valid and reliable screening 
tool for use in the general population. The EPDS is a 10-item 
self-administered questionnaire.39 The EPDS has been used 
frequently as a screening tool in non-postnatal popula-
tions.40–42 Cut-off scores range from 9–13, a score equal to or 
greater than 11 was the cut-off indicator for increased risk of 
depression in this study.
National Adult Reading Test. The National Adult Reading Test 
(NART) can be used to assess pre-morbid IQ in those with 
neurodegenerative conditions such as Alzheimer’s disease, 
but may also be used as a quick and accurate tool to assess IQ 
in a healthy population.43 The NART is relatively short and 
unaffected by poor concentration and motivation. Nelson43 
suggests that the NART is particularly useful in matching 
research participants when intelligence level may affect out-
come measures.
Biochemical analysis
Selected steroid and peptide levels were used to help provide 
an objective measure of cycle phase day; a 9-mL venous 
blood sample was drawn at each test session. Following cen-
trifugation, the sample was separated and the plasma was 
frozen to −80°C. Plasma hormone and peptide levels were 
assayed by the hospital laboratory and determined by 
Siemens Medical Solutions ADVIA Centaur XP® (prolactin, 
cortisol, oestradiol, progesterone, follicle stimulating hor-
mone (FSH), luteinising hormone (LH) and testosterone), 
IMMULITE 2000 analyser (sex hormone binding globulin 
(SHBG)) and in-house radioimmunoassay (dehydroepian-
drosterone sulphate (DHEA-S)). Coefficients of variation 
were provided by the laboratory: (a) prolactin 5.2% at 
630 mu/L, (b) 17β-oestradiol 3.0% at 3780 pmol/L, (c) pro-
gesterone 6.4% at 50 nmol/L, (d) cortisol 7.3% at 950 nmol/L, 
(e) DHEA-S 11.1% at 4.8 nmol/L, (f) SHBG 5.8% at 
20.1 nmol/L, (g) FSH 8.9% at 1.9 iU/L, (h) LH 7.6% at 
6.7 iU/L and (i) testosterone 6.9% at 3.3 nmol/L.
Statistical analysis
Stata version 1344 was used for all analyses. A repeated 
measures regression model (xtreg command) was used to 
analyse CANTAB and EPDS test scores (SRM – percent 
correct, DMS – percent correct all delays, SOC – number of 
problems solved in the minimum number of moves, IED 
shift – number of stages completed, total number of errors, 
number of errors adjusted by number of completed stages 
and EPDS – total score and number of assessments with 
score equal to or greater than 11). Phase of cycle and order of 
assessment were examined to investigate their potential 
influence on results. Follicular and luteal phase median and 
interquartile hormone and peptide level ranges were calcu-
lated and levels compared using Wilcoxon signed-rank test 
for matched pairs. Potential correlations between hormone 
and peptide levels and cognitive test scores and EPDS were 
explored.
Results
All women initially recruited returned for their second 
assessment and completed all cognitive tests, completed an 
EPDS and provided blood samples at each assessment. 
Examination of group characteristics revealed no significant 
differences in age, body mass index (BMI) or NART score 
(Table 1). The second assessment was arranged to coincide 
with each woman’s self-reported contrasting (relative to the 
first phase at testing) menstrual phase (Figure 1). Self-
reported and hormone-estimated phase group cognitive test 
scores are shown in Table 2 and EPDS results are shown in 
Table 3. There were no significant differences in any test 
score or measure of wellbeing when results were analysed by 
self-reported phase, however, when results were analysed by 
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hormone profile–estimated phase, significant phase differ-
ences were demonstrated for SRM percent correct and DMS 
probability error. Mean luteal phase EPDS score was signifi-
cantly greater compared to the follicular phase score when 
results were analysed by hormone-estimated phase com-
pared to self-reported phase (Table 3).
Phase of cycle and order of assessment effects were inves-
tigated, and no significant differences were observed for the 
majority of tests. For the DMS simultaneous and all delays 
tests, however, the group assessed first in the follicular then 
luteal phase (group 1) had significantly lower scores on both 
tests compared to the group tested first in the luteal then folli-
cular phase (group 2) (p = 0.03 and p = 0.03). Further analysis 
suggests, however, that there was no carry-over/interaction 
effect between phase of cycle and order of assessment.
Table 4 illustrates median and interquartile range (IQR) 
hormone and peptide levels for the follicular and luteal phases 
by self-reported phase, and Table 5 illustrates individual ster-
oid/peptide levels and self-reported cycle day and hormone-
estimated phase for each participant at each assessment.
Discussion
Our study demonstrates the feasibility of objective cogni-
tive testing using CANTAB across phases of the menstrual 
cycle. All women returned for repeat assessments and 
Table 2. Mean (standard error) Group CANTAB Test scores by self-reported menstrual phase and hormone profile–estimated 
menstrual phase.
Self-reported menstrual phase Hormone profile–estimated menstrual 
phase
 Follicular phase 
group
Luteal phase 
group mean
p value Follicular phase 
group
Luteal phase 
group mean
p value
SRM (% correct) 84.2 (2.8) 79.2 (3.2) 0.12 85.0 (2.8) 77.8 (3.1) 0.02
DMS all delays (% correct) 82.1 (2.5) 85.0 (3.6) 0.82 80.9 (2.3) 86.7 (3.4) 0.09
DMS simultaneous (% correct) 95.8 (2.1) 94.1 (2.4) 0.49 96.7 (2.1) 93.1 (2.4) 0.12
DMS probability error following an error 0.12 (0.04) 0.09 (0.06) 0.53 0.16 (0.03) 0.04 (0.05) 0.02
SOC total correct in minimum moves 8.3 (0.4) 7.6 (0.5) 0.15 7.9 (0.4) 8.0 (0.5) 0.8
SOC initial thinking time (ms) 5476.1 (1888.6) 7080.1 (2670.9) 0.55 5134.4 (1793.5) 7629.7 (2649.2) 0.35
SOC subsequent thinking time (ms) 553.9 (225.7) 596.3 (203.8) 0.84 731.5 (205.5) 390.3 (270.6) 0.21
IED shift stages complete 8.8 (0.1) 9 (0.2)a 0.32 8.8 (0.1) 9 (0.2)a 0.33
IED total errors 14.7 (2.3) 16.6 (1.3) 0.15 14.5 (2.3) 17.1 (1.4) 0.07
IED total adjusted errors 16.8 (3.2) 16.6 (2.0) 0.93 16.7 (3.3) 16.6 (2.3) 0.95
CANTAB: Cambridge Neuropsychological Test Automated Battery; SRM: spatial recognition memory; DMS: delayed matching to sample; SOC: stockings 
of Cambridge; IED: intra/extra dimensional.
aAll participants completed the maximum nine stages for each test phase.
Table 3. Mean (standard error) EPDS and number classified as distressed (EPDS >11) by self-reported menstrual phase and hormone 
profile–estimated menstrual phase.
Self-reported menstrual phase Hormone profile–estimated menstrual phase
 Follicular 
phase (n = 12)
Luteal phase 
(n = 12)
p value Follicular 
phase (n = 13)
Luteal phase 
(n = 11)
p value
EPDS 6.2 (1.8) 9.1 (2.0) 0.14 5.2 (1.7) 10.2 (7.3) 0.003
EPDS number with score >11 2 4 – 1  5 –
EPDS: Edinburgh Postnatal Depression Scale.
Table 1. Participant characteristics (mean with SD in parentheses).
Group 1, first test follicular (n = 6) Group 2, first test luteal (n = 6) p value
Age 33.6 (8.1) 26.8 (2.9) 0.08
BMI 23.3 (3.6) 24.5 (3.5) 0.5
NART 113.5 (6.3) 111.0 (5.6) 0.4
SD: standard deviation; BMI: body mass index (kg/m2); NART: National Adult Reading Test.
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Table 4. Serum hormone levels by menstrual phase.
Follicular phase (n = 12) median (IQR) Luteal phase (n = 12) median (IQR) p value
Oestradiol (pmol/L) 131.0 (83.3–171.8) 657.0 (341.3–1040.3) 0.002
Progesterone (nmol/L) 3.7 (2.0–4.7) 9.3 (3–29.2) 0.07
Testosterone (nmol/L) 3.01 (2.0–5.4) 3.7 (1.6–5.8) 1.0
Cortisol (nmol/L) 233.8 (154.5–306.3) 241.0 (191.2–338) 0.5
DHEA-S (umol/L) 4.4 (2.4–5.7) 3.8 (2.9–6.3) 0.24
Prolactin (mu/L) 167.5 (121.3–306.3) 178.0 (161.8–310.0) 0.69
SHBG (nmol/L) 43.0 (25.5–57.3) 55.5 (27.3–77.8) 0.09
FSH (iu/L) 6.2 (5.7–8.1) 5.35 (3.1–7.1) 0.24
LH (iu/L) 4.7 (2.1–8.6) 7.25 (3.7–17.2) 0.43
IQR: interquartile range; DHEA-S: dehydroepiandrosterone sulphate; SHBG: sex hormone binding globulin; FSH: follicle stimulating hormone; LH: lutein-
ising hormone.
biochemical estimation, suggesting this study design was 
acceptable to them. Because this was an exploratory study 
using CANTAB, formal sample size calculations were not 
undertaken. Even so when results were analysed by hor-
mone- and peptide-estimated phase opposed to self-reported 
phase, significant differences were demonstrated for the 
SRM and DMS tests. We investigated the possible influence 
of order of assessment on results and found a significant 
effect for the DMS all delays and simultaneous percent 
correct measures, subsequent analysis, however, did not 
Table 5. Individual participant serum hormone levels for each test occasion.
Self-
reported 
phase
Self-
reported 
cycle day
Hormone 
levels, 
estimated 
phase
Oestradiol 
(pmol/L)
Progesterone 
(nmol/L)
Testosterone 
(nmol/L)
Prolactin 
(mu/L)
FSH 
(iU/L)
LH 
(iU/L)
Cortisol 
(nmol/L)
DHEA-S 
(nmol/L)
SHBG 
(nmol/L)
Group 1
1 Follicular 7 Early follicular 264.10 1.9 1.79 122 7.6 5.9 152 4.1 78
– Luteal 16 Mid-luteal 1289.06 67.3 4.89 154 3 3.5 353 3.9 64
2 Follicular 10 Early luteal 296.55 11.5 2.67 145 8.2 9.2 162 2.3 58
– Luteal 21 Mid-luteal 442.62 11.7 2.0 161 9.5 12.1 174 3.0 61
3 Follicular 5 Early luteal 218.42 9.4 11.76 121 4.1 0.1 335 5.3 38
– Luteal 15 Ovulatory/
follicular
2773.68 4.2 18.52 175 7.1 18.9 396 7.4 27
4 Follicular 6 Late follicular 633.33 4.7 9.59 752 13.2 48.5 151 2.2 28
– Luteal 16 Late luteal 3700.00 22.7 2.3 274 1.4 0.8 190 3.0 27
5 Follicular 1 Early follicular 101.20 4.7 2.33 244 6.7 2.1 198 5.8 82
– Luteal 20 Early luteal 346.60 6.9 1.5 423 6.9 7.8 70 5.2 103
6 Follicular 5 Early follicular 461.90 4.0 27.19 138 6.2 3.6 259 8.9 21
– Luteal 16 Early luteal 1489.02 2.0 1.63 179 4.6 4.1 197 4.0 82
Group 2
7 Follicular 1 Late follicular 436.00 3.4 19.2 190 5.9 5.7 401 2.5 25
– Luteal 25 Late luteal 1480.77 51.2 26.61 177 3.4 8.8 294 3.0 26
8 Follicular 5 Early follicular 309.52 1.6 27.19 376 5.6 3.1 205 4.7 21
– Luteal 24 Mid-luteal 1325.00 23.6 25.0 457 1.8 1.1 211 5.4 20
9 Follicular 3 Early follicular 227.18 2.1 9.12 49 5.9 1.6 225 2.5 48
– Luteal 15 Late follicular 409.76 1.4 2.08 57 6.1 5.0 237 2.2 82
10 Follicular 6 Late follicular 433.23 4.7 9.59 752 13.2 48.5 151 2.2 27
– Luteal 17 Anovulatory/
follicular
3160.71 2.6 21.68 322 6.3 19.2 245 2.8 28
11 Follicular 5 Early follicular 205.88 2.0 5.39 115 6.1 6.6 244 5.5 51
– Luteal 21 Early luteal 940.38 31.1 7.77 164 3.7 6.7 395 6.6 52
12 Follicular 5 Early follicular 563.64 3.2 5.94 361 3.7 2.2 322 8.2 55
– Luteal 18 Early luteal 2127.12 6.5 5.74 201 14.6 41.2 283 8.0 59
FSH: follicle stimulating hormone; LH: luteinising hormone; DHEA-S: dehydroepiandrosterone sulphate; SHBG: sex hormone binding globulin.
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demonstrate a carry-over/interaction effect between phase 
of cycle and order of assessment, suggesting that the former 
significant findings for these two measures were random 
errors, possibly due to the small sample size.
The examination of hormone and peptide levels in our 
study suggests different phases to those indicated by the self-
reports of some of the participants. For example, phases 
were reversed for participant 3 in group 1 (Table 5). Our 
results suggest that fluctuation in hormone and peptide pro-
file does influence cognitive performance and wellbeing, 
and therefore, it is essential that phase of cycle is objectively 
estimated.
The inaccurate self-reporting of cycle day by some par-
ticipants in our study is critical because for some participants 
it led to assessment of cognitive performance at a time that 
did not accurately reflect the hormone/peptide levels usual 
for that phase of cycle; if self-reported phase only had been 
relied on to direct grouping for analysis, no differences 
would have been observed in test results.
Studies that have relied on self-reporting or have assayed 
few hormone and peptide levels for phase estimation risk 
inappropriate grouping for analysis, which is a possible 
explanation for the conflicting findings reported across stud-
ies. Many studies in the past have relied on counting days 
backwards from the predicted start date of menstruation. 
Counting backwards is done to improve accuracy of phase 
estimation because the luteal phase is less variable in length 
compared to the follicular phase;19 however, non-ovulatory 
cycles, which are common, will provide differing hormonal 
profiles to ovulatory cycles. More recent studies have 
reported a limited selection of hormones, for example, 
oestradiol and progesterone levels for each cycle phase,20,45 
rather than reporting a comprehensive selection of individual 
participant levels or the ranges of individual variation as we 
have done in our study.
Other hormones additional to oestradiol and progesterone 
fluctuate across the menstrual cycle and may influence cog-
nition and emotion processing and will also provide informa-
tion on cycle stage, therefore a range of hormones and 
peptides should be assayed to provide a comprehensive hor-
monal profile and sequential hormone and peptide profiling 
would be likely to provide the best estimates. We found wide 
individual variation in steroid and peptide levels which may 
influence results, though it may also be the relative differ-
ence between the nadir and peak levels that are important. A 
further biochemical consideration is the unbound proportion 
of hormone; this is the bioactive proportion not bound to 
proteins such as SHBG. Although knowledge of the unbound 
proportion is not necessary for cycle phase estimation, it 
may help understand individual performance differences and 
free oestradiol, for example, can be estimated easily by 
dividing oestradiol level by SHBG and multiplying by 100.
Although the inconsistency in results across studies may 
reflect the difficult nature of measuring complex human 
behaviour and the inaccurate grouping of participant data for 
analyses, methodological differences, including different 
assessment tools, timing of assessments, memory domains 
and sample sizes are also likely to influence results. For exam-
ple, some studies report no difference in spatial or verbal per-
formance across phases of the menstrual cycle using varying 
assessment tools.17–19 Some report improved spatial memory 
relocation test performance during the luteal phase22 and some 
report improved fragmented object identification and mental 
rotation performance during the follicular phase.21,26
Results differ however, even when the same test is used. 
For example, Maki et al.,21 using a fragmented object iden-
tification test (a measure of implicit memory), reported 
reduced object priming ability during the follicular phase, 
which correlated negatively with oestradiol level, men-
strual stage was estimated by counting forwards from the 
first day of menstruation and ‘confirmed’ by serum oestra-
diol and progesterone levels, if levels were not ‘different’ 
the participant’s data were excluded from the analyses. 
Conversely, Hampson et al.20 report no phase differences 
using the same object priming test. The method of initial 
cycle stage estimation is not reported, but was confirmed 
by salivary oestradiol levels.
The assessment of wellbeing across phases of the 
menstrual cycle has provided inconsistent results.21,23,24,46 
Behavioural intervention seems to influence the extent of 
symptoms reported,47 suggesting that psychological as well 
as physiological factors influence the degree of disturbance. 
The use of different assessment tools may explain some of 
the differences reported, for example, Symonds et al.23 report 
a lower ‘hedonia’ score for those in the luteal compared to 
the follicular phase using the University of Wales Institute of 
Science and Technology’s mood adjective checklist (UWIST-
MACL). The detection of subtle changes in affect although 
interesting, may not represent a clinically relevant difference 
or a difference that would influence cognitive performance. 
Again, inaccuracy in cycle day reporting and subsequent 
inappropriately timed assessments or grouping of data for 
analyses may account for some of the inconsistencies in 
cycle phase associated effects observed and our study find-
ings support this.
Conclusion
This study demonstrates that it is feasible to conduct objec-
tive assessment of cognitive performance using CANTAB 
across phases of the menstrual cycle. Steroid and peptide 
level estimation shows that women may inaccurately report 
cycle day, this inaccuracy may result in incorrect grouping of 
data for analyses and is likely to account for some of the 
inconsistent findings reported in the literature. We have dem-
onstrated that analysing data by hormone-estimated phase 
rather than self-reported phase can affect results.
The examination of cognitive performance using CANTAB 
and the influence of wellbeing on these measures warrants fur-
ther investigation in an adequately powered study. Studies 
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should build an accurate picture of individual participant ster-
oid and peptide profiles so that cognitive assessment and 
grouping of data for analyses can be undertaken appropriately 
and robust evidence generated.
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